Finding infections earlier is only part of the work. At IDWeek 2026, David Weber, MD, MPH, explored how broader surveillance and emerging technologies could help infection preventionists spend more time supporting safer care.
|Slideshows|January 30, 2015
Slide Show: Labs and Ebola
Advertisement
Due to a heightened concern in the United States about Ebola, the Centers for Disease Control and Prevention (CDC) has issued guidance for clinical laboratories on testing needed for the assessment and care of patients for which Ebola Virus Disease (EVD) is a concern, while minimizing risk to laboratory personnel. This document updates and replaces the previously issued guidance, "How U.S. Laboratories Can Safely Manage Specimens from Persons Under Investigation for Ebola Virus Disease."
Advertisement
Related to this article
Two experts give an update ahead of the first season with a new mRNA vaccine against flu.
Part 1 of 4: How emerging sterile processing leaders are redefining leadership through trust, accountability, psychological safety, and professional development.
This week in infection prevention: Kenya’s Bundibugyo virus response shows why execution, not just planning, determines outcomes, and France reported the first known human Shamonda virus infection. Our roundup also covers brucellosis, blood donor screening, and long-acting HIV antibody findings from IDWeek 2026.
At IDWeek 2026, Jimmy Chang, PhD, discussed investigational HIV antibodies TMB-365 and TMB-380, explaining their complementary mechanisms, early study findings, and ongoing evaluation as a long-acting maintenance regimen.
At IDWeek 2026, Samuel Ntow, MBChB, MPH, discussed research findings of reactive infection screening markers in 18.3% of replacement donor records from rural Ghana, highlighting opportunities for further evaluation and linkage to care.
France’s first reported human Shamonda virus infection raises questions about transmission and vulnerable patients. Explore what investigators know, what remains uncertain, and why infection preventionists should follow this emerging story.
John Rex, MD, CMO of F2G, discusses investigational olorofim’s phase 3 findings, why new antifungals are difficult to develop, and how an oral option could help patients with limited treatment choices.
Advertisement
Advertisement